Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710528 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT00710528 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 192 participants.
The verdict
NCT00710528, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
Interventions
- DRUG CAL-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710528
The ClinicalTrials.gov registry entry for NCT00710528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAL-101 is the first listed.
NCT00710528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710528 about?
NCT00710528 is a clinical study titled "Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies". The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
What is the current status of trial NCT00710528?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2008-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00710528?
The interventions under investigation include: CAL-101 (DRUG).
Who is sponsoring clinical trial NCT00710528?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.